Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SVF and exosome therapy for COVID-19-associated acute respiratory distress syndrome
IRCT20200510047385N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Jun 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label trial of autologous adipose stromal vascular fraction in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (4 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: SOFA score, Lung damage score and 3 more. Started Jun 2020; status: completed.
02
Drugs
autologous adipose stromal vascular fraction
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on IRCT20200510047385N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200510047385N1.